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Abstract: Vitamin K is a composite term referring to a group of fat-soluble vitamins that function as 
a cofactor for the enzyme γ-glutamyl carboxylase (GGCX), which activates a number of vitamin 
K-dependent proteins (VKDPs) involved in haemostasis and vascular and bone health. 
Accumulating evidence demonstrates that chronic kidney disease (CKD) patients suffer from 
subclinical vitamin K deficiency, suggesting that this represents a population at risk for the 
biological consequences of poor vitamin K status. This deficiency might be caused by exhaustion of 
vitamin K due to its high requirements by vitamin K-dependent proteins to inhibit calcification. 
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1. Introduction  
There are two forms of vitamin K: K1 (phylloquinone, PK) mainly found in green vegetables, 
and K2 (including different menaquinones, MKs) derived from intestinal bacteria and fermented 
food (cheeses and “natty”, a Japanese soybean product) [1,2]. Liver is also a rich source of 
menaquinones [3]. We know about more than 12 different types of MKs, from MK-4 to MK-15, but 
the most common MKs in humans are the short-chain MK-4; it is the only MK produced by systemic 
conversion of phylloquinone to menaquinones [4]. 
Vitamin K is a non-polar molecule; after its intestinal absorption, vitamin k is solubilised by bile 
salt and pancreatic juice; vitamin K is then packaged into chylomicrons which are secreted into the 
lymphatic system [5]. For this reason lipids, in particular triglycerides, interfere with vitamin K 
measurement. 
Vitamin K is as a substrate for an enzyme, the vitamin K-dependent carboxylase, that converts 
specific glutamic acid residues of a small number of proteins to -glutamic carboxyl (Gla) residues by 
the addition of a CO2. Vitamin K is necessary to introduce carboxyl groups into glutamic acid 
residues in blood coagulation factors (II, VII, IX, X) to yield Gla residues [6]; Gla-containing proteins 
include osteocalcin (OC), synthesized by the osteoblasts in bone, and matrix Gla protein (MGP), 
synthesized by chondrocytes and vascular smooth muscle cells (VSMCs), involved in bone 
mineralization and inhibition of vascular calcifications, respectively.  
2. Vitamin K Deficiency 
Indirect functional tests can be assessed to detect vitamin k levels, such as the prothrombin time 
or measurement of undercarboxylated proteins OC and MGP, which are more sensitive in detecting 
subclinical vitamin K deficiency than prothrombin time [6]. This measurement is possible because 
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vitamin K-dependent proteins (VKDP) cannot attain their carboxylation status (and they remain 
undercarboxylated) in the presence of vitamin K deficiency; this condition causes the loss of their 
capacity to bind calcium, so that bone metabolism may be impaired and the process of vascular 
calcification enhanced [7]. A high percentage of undercarboxylated OC (uOC) reflects vitamin K 
intake and the long-term vitamin K status. Osteocalcin levels are also influenced by vitamin D, 
which is required for the production of uOC, and by parathyroid hormone (PTH), which is 
frequently elevated in CKD patients [6,8,9]. Therefore, chronic kidney disease (CKD) patients with 
hyperparathyroidism will present high serum uOC, but this does not necessarily mean that they are 
vitamin K deficient. 
A good alternative to evaluate vitamin K status is through the inactive form of MGP, even if 
inactive MGP may only reflect the vitamin K status at the vascular level and not at bone or liver. 
Indeed, randomized controlled studies have shown that vitamin K therapy decreases 
undercarboxylated unphosphorylated MGP (uc-dp-MGP) levels [9–11]; in contrast, anti-vitamin K 
(AVK) treatment increased the amount of inactive uc-dp-MGP [12] and stopping that treatment 
decreased uc-dp-MGP [13]. All these data suggest that uc-dp-MGP could be a good marker of 
vitamin K status [6]. 
3. Vitamin K Status in CKD Patients 
Evidence demonstrates that CKD patients suffer from subclinical vitamin K deficiency [14], 
suggesting that this population is at risk for any consequences of poor vitamin K status. This 
deficiency might be caused by exhaustion of vitamin K due to its high requirement by vitamin 
K-dependent proteins to inhibit calcification. However, dietary recommendations for CKD patients, 
such as diets low in potassium (fewer leafy green vegetables rich in K1) and low in phosphate (fewer 
dairy products rich in K2) could promote this deficiency. 
Considering that vitamin K is essential for the activation of matrix Gla protein (MGP), a 
powerful inhibitor of tissue calcification, functional vitamin K deficiency may contribute to high 
vascular calcification (VC) burden in haemodialysis patients; this is process in which mineral is 
pathologically deposited in blood vessels, mainly in large elastic and muscular arteries such as the 
aorta and the coronary, carotid, and peripheral arteries. The presence of VC is directly related to 
increased cardiovascular morbidity and mortality in dialysis patients [15].  
Circulating non-phosphorylated non-carboxylated MGP, which is formed as a result of vitamin 
K deficiency in CKD, is associated with cardiovascular disease and with overall survival [16]; in 
contrast, in older individuals without CKD, non-carboxylated MGP was linked to abnormal vitamin 
K status, but not to coronary artery calcium content [17]. Shea et al. [17] reported the latter condition, 
and these findings are in contrast with results of case–control studies reporting higher plasma 
ucMGP among patients with diseases characterized by vascular calcification and kidney disease; 
however, the prior studies did not measure CAC directly as they have. Furthermore, the ucMGP 
may be a marker for other risk factors, such as hyperlipidaemia and hypertension [17]. 
Schurgers et al. measured dpucMGP in a cohort of 107 patients ranging from CKD stages 2–5D, 
and reported that levels of plasma dp-ucMGP increased progressively with CKD stage. They 
showed, therefore, a decline in this biomarker with reduction in GFR [18]; the risk of vascular 
calcification is presumed higher if the calcification-inhibitory effect of MGP is impaired. Pre-clinical 
studies confirm that diminished vitamin K status influences the severity of arterial calcification in 
rats with CKD that can be prevented by a diet rich in vitamin K1 [19]. 
Holden et al., in a study of 172 stage 3–5 CKD patients, demonstrated that over 50% consumed 
less than the recommended adequate intake for vitamin K; moreover, 6% were vitamin 
K-insufficient according to low levels of serum phylloquinone (<0.4 ng/mL), 60% were insufficient 
according to high levels of ucOC (>20% ucOC), and 97% were insufficient according to high levels of 
protein-induced vitamin K absence or antagonist II (PIVKA-II) (>2 nmol/L) [20]. 
Several studies focused on the vitamin K status in haemodialysis (HD) patients [21]. On account 
of its lipophilic characteristics, vitamin K would not be expected to be removed via the dialysis 
procedure but there is a growing and consistent body of evidence supporting the notion that 
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maintenance HD patients have a global poor vitamin K status; while the exact reason for the low 
intake is unknown, it is likely related to the dietary regimen prescribed for HD patients and overall 
poor nutrient intake. 
As reported by Westenfeld et al., at baseline, haemodialysis patients had 4.5-fold higher 
dephosphorylated, uncarboxylated MGP and 8.4-fold higher uncarboxylated osteocalcin levels 
compared with controls [11]. Cranenburg et al. measured and assessed vitamin K1 and K2 intake 
and the vitamin K status in 40 haemodialysis patients: the intake was low in these patients (median 
140 µg/day), especially on days of dialysis and the weekend as compared to intakes reported in a 
reference population of healthy adults (mean K1 and K2 intake 200 and 31 µg/day, respectively) [22]. 
In response to poor dietary intake, body stores of vitamin K are rapidly depleted. 
Undercarboxylated vitamin K-dependent bone and coagulation proteins were found to be elevated 
in 33 haemodialysis patients, indicating subclinical hepatic vitamin K deficiency. Very high 
non-carboxylated MGP levels, endemic to all patients, also strongly suggested vascular vitamin K 
deficiency. 
Voong et al. reported that 29% and 93% of maintenance HD patients met criteria for sub-clinical 
vitamin K deficiency based on low levels of phylloquinone and high levels of ucOC, suggesting 
there is also vitamin K deficiency at the level of bone [23]. 
Some studies demonstrated that peritoneal dialysis (PD) patients have a similar degree of 
vitamin K insufficiency as maintenance HD patients: in a study of 28 PD patients, 46% had vitamin K 
deficiency as measured by elevated PIVKA II levels (>2 nM/L) [24]. In a cross-sectional study of 21 
PD patients, it was demonstrated that 24% of them had vitamin K deficiency as assessed by serum 
K1 (<0.4 nM/L) and all patients had vitamin K deficiency as assessed by increased percentage of 
ucOC (>20% was the cut off for vitamin K deficiency, mean was 60%) [25]. 
Jansz et al. studied the influence of kidney transplantation and phosphate binder use on 
vitamin K status and found that kidney transplant recipients have substantially lower dp-ucMGP 
levels compared to patients on haemo- or peritoneal dialysis, indicating better vitamin K status after 
restoration of kidney function. In general, instead, phosphate binder use is not associated with 
dp-ucMGP levels except for sevelamer monotherapy. which is associated with significantly higher 
dp-ucMGP levels, suggesting a negative effect of sevelamer on vitamin K status [26]. 
4. Anti-Vitamin K Treatment and Effects—Warfarin 
Warfarin is a vitamin K antagonist; its use represents a model of vitamin K insufficiency. It 
induces arterial calcification in experimental models, but whether this occurs in humans is unclear.  
Tantisattamo et al. [27] examined breast arterial calcification identified on mammograms. 
Screening mammograms from women with current, past, or future warfarin use were examined for 
the presence of arterial calcification and compared with mammograms obtained in untreated 
women matched for age and diabetes mellitus. In 451 women with mammograms performed after 
≥1 month of warfarin therapy, the prevalence of arterial calcification was 50% greater than in 451 
untreated women (39.0% versus 25.9%; p < 0.0001). This study showed that the prevalence of breast 
arterial calcification is increased in women with current or past warfarin use independent of other 
risk factors and conditions predating warfarin use; this effect may be irreversible and appears to be 
cumulative. 
McCabe at al. [19] wanted to determine whether modifying vitamin K status, either by 
increasing dietary vitamin K intake or by antagonism with therapeutic doses of warfarin, could alter 
the development of vascular calcification in male Sprague–Dawley rats with adenine-induced CKD. 
Pulse pressure and pulse wave velocity were increased after treatment with warfarin in CKD rats, as 
well as calcium concentrations in the thoracic aorta (3-fold), abdominal aorta (8-fold), renal artery 
(4-fold), and carotid artery (20-fold) were significantly increased. It is interesting to notice that 
therapeutic warfarin did not induce calcification in the blood vessels of healthy rats despite 
depletion of tissue vitamin K; in contrast, compared with CKD alone, warfarin markedly increased 
the levels of vascular calcification in all vessels studied in the presence of CKD.  
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Thus, vitamin K has an important role in modifying mechanisms linked to the susceptibility of 
arteries to calcify in an experimental model of CKD. 
As well as presenting a greater risk of development of vascular calcifications due to secondary 
hyperparathyroidism, haemodialysis patients are frequently treated with vitamin K antagonists, 
mainly to prevent stroke in atrial fibrillation, potentially compounding the cardiovascular risk in 
these already vulnerable patients. Warfarin may predispose to different side effect, such as bone 
fractures and vascular calcification, by different mechanisms: directly, by inhibition of 
-carboxylation of OC and other bone matrix proteins; indirectly, because patients treated with 
warfarin may limit their dietary intake of foods rich in vitamin K [18,19].  
4.1. Bone Fracture  
Studies on bone fractures in CKD patients are limited. According to the available literature, the 
prevalence of vertebral fractures in dialysis patients appears to be similar to the general population, 
between 20.9% and 26.5% [28,29]; however Rodriguez-Garcia et al. [30] demonstrated a positive, 
significant correlation between vertebral fractures and vascular calcification in the dialysis 
population. This is probably due to underdiagnosis of vertebral fractures both in the general and in 
the dialysis population; this hypothesis was confirmed by the unpublished data of Fusaro et al., in 
which a vertebral fracture prevalence of 57% was found in a population of 68 haemodialysis patients 
[7]. Alem et al. studied the incidence of hip fractures and they found a considerably higher risk of 
hip fracture among dialysis patients than in general population [31]. 
Kohlmeier et al. were the first to demonstrate an independent association between poor vitamin 
K status and risk of bone fracture in patients in haemodialysis [32], while Fusaro et al. conducted an 
observational study of 387 prevalent HD, determining that over 50% of prevalent haemodialysis 
patients have vertebral fractures [33]. In this study, vitamin K1 deficiency (defined as a 
phylloquinone level adjusted for serum triglycerides <0.21 ng/mL), was the strongest predictor for 
the presence of a vertebral fracture (an adjusted odds ratio approaching 3). 
In another study, Fusaro et al. found that haemodialysis patients treated with warfarin for 
greater than 1 year had an increased risk of vertebral fractures compared to those not on warfarin 
treatment [34]. With regard to vitamin K administration for the prevention of fractures, 13 
randomized controlled studies with vitamin K1 and K2 treatment lasting for a minimum of 6 months 
were the subject of a meta-analysis [35]: 11 of these studies were from Japan, and seven reported 
fracture data. The subjects recruited in the studies were mainly menopausal women. All but one 
studies showed an advantage of vitamin K in reducing bone loss. All seven trials that reported 
fracture effects were from Japan and used vitamin K2 (menaquinone). Pooling the seven trials with 
fracture data in a meta-analysis, an odds ratio favouring menaquinone of 0.40 (95% confidence 
interval (CI), 0.25–0.65) for vertebral fractures, an OR of 0.23 (95% CI, 0.12–0.47) for hip fractures, 
and an OR of 0.19 (95% CI, 0.11–0.35) for all nonvertebral fractures were reported.  
4.2. Cardiovascular Calcification  
The first study [36] demonstrating strongly increased calcification of the aortic valves in 
patients taking oral anticoagulants—including warfarin and acenocoumarol—has been confirmed 
by many other researchers: Koos et al. demonstrated that subjects taking vitamin K antagonist 
anticoagulants had a significantly higher degree of arterial and aortic valve calcification than control 
subjects [37]. In a case report, Hristova et al. described a kidney transplant recipient exhibiting 
massive arterial calcification after the initiation of warfarin therapy [38]. Distal subcutaneous 
necrosis ultimately led to the patient’s death. Rennenberg et al. showed rapid calcification of the 
femoral artery when patients are treated with oral anticoagulants, (OR 8.5; 95% confidence interval 
(CI) 2.01–35.95, for calcification in patients compared with controls) [39]. Similarly, patients taking 
oral anticoagulants showed significantly increased levels of coronary calcification [40]. 
4.3. Calciphylaxis 
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Approximately 1% of CKD patients develop calciphylaxis, a frequently fatal complication of 
end-stage renal disease. Notably, about 50% of patients with CKD stage 5D (CKD5D) who develop 
calciphylaxis are on vitamin K antagonists (VKAs) [41]. Compared to the dialysis patients 
worldwide, the overall number of calciphylaxis cases is minimal. However, in their case–control 
analysis, Hayashi et al. [42], calculated an 11.4-fold increased risk of developing calciphylaxis in 
Japanese dialysis patients on warfarin.  
In the pilot case–control study by Nigwekar et al. the authors demonstrated that patients with 
calciphylaxis in end stage renal disease (ESRD) had proportionally higher plasma levels of the 
inactive ucMGP than dialysis controls. They investigated how MGP carboxylation influenced the 
risk of calciphylaxis in 20 patients receiving haemodialysis with calciphylaxis (cases) and 20 patients 
receiving haemodialysis without calciphylaxis (controls); case patients had higher plasma levels of 
ucMGP and carboxylated MGP (cMGP) than controls. However, the fraction of total MGP that was 
carboxylated (relative cMGP concentration = cMGP/(cMGP + uncarboxylated MGP)) was lower in 
cases than in controls (0.58 ± 0.02 versus 0.69 ±0.03, respectively; p = 0.003). The authors concluded 
that a vitamin K deficiency-mediated reduction in relative cMGP concentration may have a role in 
the pathogenesis of calciphylaxis [43]. 
Krueger et al. believe that vitamin K, and especially vitamin K2, supplementation may become 
an important option in the standard treatment for calcification-prone CKD patients [44]. 
4.4. Arteriovenous Fistula Failure 
Arteriovenous fistula (AVFs) is a frequently used vascular access type for CKD patients 
requiring haemodialysis (HD) [45]. AVF failure is a complication leading to high hospitalization 
rates and morbidity [46]. Whereas early AVF failure is caused by thrombosis or by inability of the 
vein to dilate, later course AVF failure is induced by stenosis and thrombosis resulting from 
neointimal hyperplasia (NIH) and calcification [47,48]. Recent work indicates that AVF calcification 
contributes to AVF failure [49]; in arterialized veins, calcification occurs in tunica media and intima. 
HD patients have a poor overall vitamin K status, and a high number of CKD patients at risk of 
arterial and venous thrombosis receive oral anticoagulants (vitamin K antagonists; VKAs) [50]. It has 
been shown that VSMCs from varicose veins increased calcification when treated with warfarin, 
indicating similar processes in venous and arterial VSMCs [51]. Vascular access calcification is an 
independent predictor of mortality, whereas nothing is known about effects of VKA on AVF, NIH, 
and calcification. 
The objective of the study of Zaragatski et al. was to investigate the effects of vitamin K 
antagonists and vitamin K2 treatment on neointimal hyperplasia development and calcification in 
rats and in arterialized human veins [52]. AVF was generated in female rats while chronic kidney 
disease was induced using an adenine-enriched diet. Arterialization, CKD, and vitamin K 
antagonists all significantly enhanced venous neointimal hyperplasia. K2 treatment and vitamin K 
antagonists significantly reduced neointimal hyperplasia in arterialized veins in healthy rats but not 
in rats with CKD. Arterialization, CKD, and vitamin K antagonism all significantly increased, 
whereas K2 supplementation attenuated calcification in healthy rats and rats with CKD. 
K2 significantly enhanced matrix Gla protein carboxylation in control rats and rats with CKD. 
Arterialized human vein samples contained inactive matrix Gla protein at calcification and 
neointimal hyperplasia sites, indicating local vitamin K deficiency. Thus, vitamin K antagonists have 
detrimental effects on AVF remodeling, whereas K2 reduced neointimal hyperplasia and 
calcification indicating vasoprotective effects. Hence, K2 administration may be useful to prevent 
neointimal hyperplasia and calcification in arterialized veins. 
5. New Oral Anticoagulant vs. Warfarin 
New oral anticoagulants (NOACs) are valid alternatives to vitamin K antagonists in the general 
population, but their use in dialysis has been limited by substantial renal clearance. 
Dabigatran and rivaroxaban have not been studied in end-stage renal disease patients who 
were specifically excluded from two large randomized trials that were conducted in patients 
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without renal failure [53,54]. In dialysis patients, prescription of these novel oral anticoagulant drugs 
(NOACs) is currently contraindicated because the drugs are cleared by kidneys and drug levels can 
bio-accumulate to precipitate bleeding; as demonstrated by Chan et al., the unadjusted event rate of 
major bleeding increased with drug dosage [55]. The study of Chan et al. is the first to evaluate these 
drugs in the dialysis population, and suggests concern given the increasing use of dabigatran and 
rivaroxaban in the ESRD population despite formal FDA warnings of caution in renal failure. In fact, 
their secondary analyses suggest excess morbidity and mortality from bleeding associatively higher 
with dabigatran and rivaroxaban when compared to warfarin [55]. 
Among the available NOACs, apixaban has the lowest renal elimination. Both dabigatran and 
rivaroxaban were associated with increased bleeding in dialysis patients but recently apixaban was 
non-inferior to warfarin in a large database study. 
Siontis et al. [56] conducted a retrospective cohort study in patients with ESRD and atrial 
fibrillation (AF) in dialysis who initiated treatment with apixaban or warfarin. Standard dose of 
apixaban (5 mg twice a day) was associated with significantly lower risks of stroke/systemic 
embolism and death as compared with either reduced dose of apixaban (2.5 mg twice a day; n = 
1317; HR 0.61, 95% CI 0.37–0.98, p = 0.04 for stroke/systemic embolism; and HR 0.64, 95% CI 
0.45–0.92, p = 0.01 for death) or warfarin (HR 0.64, 95% CI 0.42–0.97, p = 0.04 for stroke/systemic 
embolism; and HR 0.63, 95% CI 0.46–0.85, p = 0.003 for death). The authors concluded that, among 
ESRD patients with AF on dialysis, apixaban use may be associated with lower risk of major 
bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with 
reductions in thromboembolic and mortality risk. 
6. Phosphate Binders 
Chronic kidney disease mineral bone disorders (CKD-MBD) is a complex syndrome in dialysis 
patients, which includes alterations of biochemical parameters of the mineral and bone metabolism, 
a clinically and histologically manifested bone disease and vascular calcifications associated with an 
increased risk of cardiovascular morbidity and mortality. One of its most frequent components is 
hyperphosphatemia, which has traditionally been treated with dietary restrictions and intestinal 
phosphorus binders [57]. 
It is unknown if the use of phosphate binders, especially calcium based binders, may actually be 
harmful [58]. There is some attenuation or delay of progression of VC by the noncalcium-based 
phosphate binders as compared to the calcium containing binders [59–61]. However VC frequently 
progresses despite adequate phosphate concentrations; probably due to chronic inflammation, 
increasing calcium load from calcium based binders and other factors such as vitamin K deficiency. 
In their study, Neradova et al. set up a study in which vitamin K2 (menaquinone-7; MK-7) was 
mixed with five different phosphate binders, in presence or absence of phosphate, incubated at pH 6 
and fixed temperature of 37 degrees Celsius. In particular, 1 mg of vitamin K2 was added to a 
medium with pH 6 containing 67 mg phosphate binder with either 7 mg of phosphate or no 
phosphate [62]. 
This experiment showed that sucroferric-oxyhydroxide and sevelamer carbonate were the only 
binders that did not bind vitamin K2 in vitro. This in vitro study demonstrated that calcium 
acetate/magnesium carbonate binds vitamin K2 strongly both in absence (p = 0.001) and presence of 
phosphate (p = 0.003). For Lanthanum carbonate this binding depends on the absence of phosphate, 
pointing to competitive binding between phosphate and vitamin K2 for this compound (p = 0.005) 
whereas no significant binding of vitamin K2 was observed in the solution containing vitamin K2 
and phosphate (p = 0.462). Calcium carbonate binds vitamin K2 statistically and significantly in a 
solution with vitamin K2 and phosphate (p = 0.009), whereas without phosphate no significant 
binding of vitamin K2 was observed (p = 0.123). In the mixture with sevelamer carbonate a 
nominally lower concentration of K2 was shown as well, but this decline was not statistically 
significant. Addition of sucroferric-oxyhydroxide did not lead to any decline of vitamin K2 at all, 
irrespective of presence or absence of phosphate. 
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The authors did not study the chemical explanation for this feature, but possibly the formed 
calcium-phosphate salt itself binds K2 as well. In conclusion, the presence or absence of phosphate 
significantly interferes with vitamin K2 binding, so phosphate binders could potentially limit the 
bioavailability of vitamin K2. 
According to these results, in HD patients, in which phosphorus levels are usually elevated, 
phosphate binders that do not bind vitamin K in the presence of phosphate should be selected. 
7. Drug and Vitamin K-Dependent Protein (VKDP) 
Fusaro et al. carried out a sub-analysis to evaluate associations between drug consumption and 
VKDP levels in 387 haemodialyzed patients [63]. The VIKI study was an observational study 
performed in 387 adult patients of both genders who had been on dialysis for more than 1 year at 18 
centres in Italy between November 2008 and November 2009. It was designed primarily to assess the 
prevalence of deficiency of vitamin K1 and vitamin K2 in dialysis patients. In this sub-study the 
authors evaluated drug consumption, determined bone Gla proteins (BGP) and MGP levels, and 
verified the presence of any vertebral fractures (VF) and VC by spine radiographs. Regarding 
mineral and bone disorder treatment, the most common were oral calcitriol (45.7%) and sevelamer 
(42.1%). 
Total BGP levels were twice as high with calcimimetics versus no calcimimetics (290 vs. 158.5 
mcg/L, p < 0.0001) and 69% higher with vitamin D analogues (268 vs. 159 mcg/L, p < 0.0001). Total 
MGP was 19% higher with calcimimetics (21.5 vs. 18.1 mcg/L, p = 0.04) and 54% higher with calcium 
acetate (27.9 vs. 18.1 mcg/L, p = 0.003); no difference was found with vitamin D analogues. This 
finding of increased MGP in patients treated with calcimimetics is the first in humans and it is 
consistent with the results of in vitro and in vivo experimental studies, in which MGP was measured 
before and after the administration of the calcimimetic [64–66]. 
Median Total BGP level was 29% lower in patients with ≥1 VF (151 vs. 213 mcg/L, p = 0.0091) 
and 36% lower in patients with VC (164 vs. 262.1 mcg/L, p = 0.0003). In non-survivors, median BGP 
and MGP were lower, but this difference reached the statistical significance for MGP only (152 vs. 
191 mcg/L, p = 0.20 and 15.0 vs. 19.7 mcg/L, p = 0.02, respectively). No significant association between 
MGP levels and VF or VC was found, despite an association between high MGP levels and survival. 
Pending studies on vitamin K supplementation, calcimimetics, and vitamin D analogues may 
play a role in preserving vitamin K-dependent protein activity, thus contributing to bone and 
vascular health in CKD patients. 
8. Vitamin K Supplementation 
The question therefore arises of whether CKD patients might benefit from extra vitamin K 
intake. In the population-based Rotterdam study [67], dietary intake data including vitamin K were 
available for 4800 elderly patients. The authors assessed the risk of incident coronary heart disease, 
all-cause mortality, and aortic calcification based on tertiles of energy-adjusted vitamin K intake. 
They found that low vitamin K2 intake was associated with a higher incidence of severe aortic 
calcification and increased mortality. In line with this observation, a recent pilot study investigated 
whether daily vitamin K2 supplementation would improve the bioactivity of vitamin K-dependent 
proteins in CKD5D patients: after only 6 weeks of daily vitamin K2 supplementation, a significant 
decrease in dp-uc-MGP, ucOC, and uncarboxylated factor II (ucFII) levels was observed. This shows 
that vitamin K is able to reach tissues, including the vessel wall, and to correct the biochemical and 
local tissue consequences of vitamin K deficiency. 
A supplementation in vitamin K in particular in HD an PD patients should be taken into 
account, considering the poor vitamin K status in CKD patients. One randomized controlled trial 
evaluated the response of biomarkers of vitamin K status (dp-uc-MGP, PIVKA-II and ucOC) to three 
doses of vitamin K2 (MK-7) administered over a period of 6 weeks in HD patients and the study 
reported that vitamin K2 (MK-7) supplementation decreased dp-uc-MGP and PIVKA-II levels [11]. 
Shea et al. reported that supplementation with daily phylloquinone (0.5 mg) slowed the progression 
of cardiovascular calcification (CAC) over 3 years in healthy older adults with pre-existing CAC at 
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baseline [68]; it is well established that patients with kidney failure have an increased risk for both 
vascular calcification and sub-clinical vitamin K deficiency but yet no trial that examines whether 
vitamin K supplementation prevents the progression of calcification in this population has been 
completed. 
Furthermore, vitamin K status after kidney transplantation may play an important role. In a 
study made by Keyzer et al. [69], vitamin K deficiency was an important risk factor of overall 
mortality in kidney-transplanted patients. 
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